NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Prokidney Corp. PROK
6 fiscal years on record · USD · FY2025 reported · SEC filings only
In brief
What this company does
Written from the business description in ProKidney Corp.'s annual report to the U.S. Securities and Exchange Commission, filed 18 March 2026. Every sentence was checked against that document before publication.
Growth
USD 893,000.00
Revenue, FY2025 · full 6-year series below
Revenue $M
Net income $M
FY2025 · Revenue 0.9 · Net income -69.0
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−16978 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -18477.8% · Net -16977.8%
ROE
No chart to show — the reason differs by year; see each year in the table below.
The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | · | · |
| Operating income $B | −0.2 | −0.2 | −0.2 | −0.2 | −0.1 | −0.0 |
| EBITDA $B | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.0 |
| Income tax $B | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 |
| Net income $B | −0.1 | −0.1 | −0.0 | −0.1 | −0.1 | −0.0 |
| Free cash flow $B | −0.1 | −0.2 | −0.1 | −0.1 | −0.1 | −0.0 |
| EPS, diluted $ | · | · | · | −0.23 | · | · |
| Dividend / sh $ | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · |
| ROE % | · | · | · | · | −299.9 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 1 failures in 17 reconciliationsAUDITED
Reconciled in 5 of 19 fiscal years. 59 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inoutside the United States — SEC code E9
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2020